[BBIO Q2 2026 Earnings Call] Attruby Sales Hit $222M, Surge 120%, as BridgeBio Maps ‘Launch 2.0’ with $1.7B War Chest — BigGo Finance
BridgeBio Pharma (BBIO) reported Q2 2026 Attruby net product revenue of $222.4M, up from $71.5M a year earlier, and total revenue up 120% to $243.7M. Management said it has $1.7B cash after a $1B preferred equity deal. The company discussed CARDIO-TTRansform failure, regulatory progress on three NDAs, and expects breakeven toward 2027.
How this was made
The 30-second read
Why it matters
Near-term trading focus is on (1) the magnitude of Attruby revenue acceleration, (2) the $1.0B preferred equity closing that extends funding runway, and (3) FDA submission and priority review milestones for three late-stage programs, while the CARDIO-TTRansform miss introduces uncertainty around combination-therapy expectations.
Market read
This is a multi-catalyst earnings call with hard quarterly revenue numbers, a large capital raise, and multiple FDA submission/priority review dates, making it actionable for BBIO positioning.
What to watch
The article emphasizes RWE and early kidney-protection claims, but it also notes translation to prescribing behavior may take 6 to 9 months, creating a timing gap between data and revenue realization.
Background
BridgeBio used its Q2 2026 earnings call to frame “Launch 2.0” around Attruby growth, additional clinical/regulatory signals, and a strengthened balance sheet.
Ticker impact
BridgeBio reported Q2 2026 Attruby net product revenue of $222.4M, up 211% YoY, and outlined a $1.7B cash war chest for three near-term launches.
Likely positive bias for BBIO as investors price in faster commercialization and improved funding runway, though CARDIO-TTRansform failure may cap upside until ESC/next datasets.
The article contains multiple primary, decision-relevant disclosures: quarterly revenue datapoints, a $1.0B preferred equity closing to ~$1.7B cash, and FDA submission/priority review milestones for three late-stage programs, offset by a major trial miss.
Market effects
Reinforces investor appetite for ATTR cardiomyopathy commercial leaders and rare-disease franchises with near-term FDA catalysts.
Limited direct regional read-through; mentions Europe and Japan partner revenue but no new regional policy/regulatory action.
Potential read-across to cardiovascular and rare-disease treatment paradigms, especially first-line positioning and real-world evidence use.
Counterpoint
The CARDIO-TTRansform trial failure could delay or limit peak-share assumptions, and management’s guidance updates are described as “too early,” leaving valuation vulnerable to skepticism.
Key entities
- companyBridgeBio Pharma
BBIO, reported Q2 2026 financials and outlined late-stage regulatory milestones and funding via preferred equity.
- productAttruby
A treatment for ATTR cardiomyopathy; Q2 2026 net product revenue reached $222.4M, up 211% YoY.
- clinical_trialCARDIO-TTRansform trial
Tested AstraZeneca and Ionis’s eplontersen on top of background stabilizers; missed its primary endpoint.
- investorSixth Street
Led the $1.0B preferred equity investment that took pro forma cash to about $1.7B.
